Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health ...

Zoetis faces ongoing headwinds as Librela sales disappoint, triggering a sharp post-earnings sell-off and continued stock weakness. Librela's decline, fueled by social media concerns about side ...

Fintel reports that on November 5, 2025, UBS maintained coverage of Zoetis (NYSE:ZTS) with a Neutral recommendation. Analyst Price Forecast Suggests 60.35% Upside As of October 29, 2025, the average ...

Zoetis Inc. (NYSE:ZTS) Q3 2025 Earnings Call Transcript November 4, 2025 Zoetis Inc. beats earnings expectations. Reported EPS is $1.7, expectations were $1.62. Operator: Good morning, everyone, and ...

We recently published 10 Stocks Lead Wall Street Downward Spiral. Zoetis Inc. (NYSE:ZTS) is one of the worst-performing stocks on Tuesday. Zoetis fell to a new 52-week low on Tuesday, as investor ...

Zoetis, Inc. ZTS delivered third-quarter 2025 adjusted earnings (excluding one-time items) of $1.70 per share, which surpassed the Zacks Consensus Estimate of $1.62. In the year-ago quarter, the ...

Zoetis (ZTS) came out with quarterly earnings of $1.7 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.58 per share a year ago. These figures are ...

Shares of animal health company Zoetis (NYSE:ZTS) fell 12.6% in the morning session after the company reported mixed third-quarter results and cut its full-year sales forecast. Although its adjusted ...

It was a marching order long before it became the name of Ford's new line of small sedans, hatchbacks, and wagons. Engineers were ordered to protect their interior package from the stylists who might ...